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Abstract 
Since the 1980's, novel functional roles of the neurohypophyseal hormones vasopressin and 
oxytocin have emerged. Several studies have investigated the effects of these two 
neurohormones on striated muscle tissues, both in vitro and in vivo. The effects of vasopressin 
on skeletal myogenic cells, developing muscle and muscle homeostasis have been 
documented. Oxytocin appears to have a greater influence on cardiomyocite differentiation 
and heart homeostasis. This review summarizes the studies on these novel roles of the two 
neurohypophyseal hormones, and open the possibility of new therapeutic approaches for 
diseases affecting striated muscle. 
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 Arginine-vasopressin (AVP), also known as 
antidiuretic hormone, and oxytocin (OT) are two 
neurohormones released by the posterior hypophysis. 
These nonapeptides are synthesized in magnocellular 
neurons of the paraventricular and supraoptic nuclei of 
the hypothalamus.
1
 They are processed along the 
axonal projections to the neurohypophysis, stored in 
secretory vesicles and released, in response to a 
plethora of physiological stimuli, into the bloodstream, 
through which they reach distant targets and participate 
in the regulation of numerous functions that are crucial 
for survival.
2,3
 The only difference between AVP and 
OT lies in two amino acids. However, despite their 
structural similarity, these two neurohormones exert 
different physiological functions.  
In mammals, OT plays an important role in 
reproduction by inducing uterus contraction upon labor 
and by increasing milk delivery during lactation.
4,5
 OT 
is also released in the brain, where it acts as a 
neuromodulator. Animal and human studies 
demonstrate that OT plays a role in social and sexual 
behaviors, in mood regulation in humans (likely 
through inhibition of amygdala activity), as well as in 
some behavioral disturbances, such as autism and 
obsessive-compulsive disorders.
6–10
 AVP, on the other 
hand, plays an essential role in regulating whole-body 
water balance, predominantly by modulating the 
expression and function of the water channel 
aquaporin-2 and of the urea transporters in the 
epithelial cells of the nephron collecting duct.
11
 In 
addition, AVP is a vasoconstrictor that increases 
peripheral vascular resistance, leading to increased 
arterial blood pressure.
3
 Like OT, AVP exerts direct 
effects on the brain: experiments on cognitive 
processes have demonstrated that both neurohormones 
enhance memory and attention.
6,8
 Unlike OT, AVP 
exerts an excitatory action on neural transmission.
2
 
In addition to their well-documented role in the CNS, 
AVP and OT play important biological roles in many 
peripheral organs and tissues. While AVP mediates 
stress by triggering adrenocorticotropic hormone 
(ACTH) release, OT exhibits anti-stress properties. 
Moreover, both AVP and OT play a marked role in 
cardiac homeostasis. AVP has been found to make a 
significant contribution to the progression of 
hypertension and heart failure, while OT has been 
found to reduce blood pressure and promote cardiac 
healing.
3,12,13
 The actions of OT include water body 
balance, modulation of the parasympathetic system, 
induction of NO-dependent vasodilatation, endothelial 
cell growth and anti-inflammatory response. 
In addition, the extensive presence of a functional OT 
system in the early developing heart and the capacity 
of OT to induce the differentiation of mouse 
embryonic stem cells into cardiomyocytes provide 
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additional evidence of its role in the cardiovascular 
system.
14
  
Until a few decades ago, neurohypophyseal hormones 
were not known to exert effects on skeletal muscle. 
This topic has emerged as a novel subject in the last 
three decades following studies conducted in various 
laboratories, including ours. In 1982, Wakelam et al. 
documented a modest effect of AVP on carbohydrate 
metabolism in chick embryo muscle cell cultures,
15
 and 
later demonstrated the presence of functional AVP 
receptors in the rat myogenic L6 cell line.
16
 AVP levels 
were subsequently reported to be very high in 
developing skeletal muscle, and to decline during 
gestation, reaching very low levels at birth,
17
 thus 
suggesting that this hormone is involved in the early 
phases of muscle development. More recently, Breton 
et al. provided evidence that functional OT receptors 
are present in human primary myoblasts.
18
 
These observations suggest that neurohypophyseal 
hormones may play a role during skeletal myogenesis 
and might help maintain skeletal muscle homeostasis. 
In our first paper on this subject,
19
 we reported 
important responses elicited by AVP in myogenic 
cells, which included generation of inositol phosphates 
and increased cytosolic free calcium concentrations. 
We also demonstrated that the responsiveness to AVP 
of different myogenic cell lines and clones positively 
correlated with their myogenic potential. 
In this review, we summarize the effects that AVP and 
OT have been reported to exert on skeletal muscle in 
recent decades to highlight the role of these hormones 
in skeletal muscle biology. 
Neurohypophyseal hormone receptors 
Both oxytocin and vasopressin receptors are 
heptahelical transmembrane proteins that activate G 
proteins. Three types of AVP receptor are known: V1a, 
V1b and V2, which differ in localization, function and 
signal transduction mechanisms. The V1a and V1b 
receptors activate phospholipases A2, C and D; V2 
receptors regulate adenylate cyclase activity.
20,21
 The 
V1a receptors (V1aR) are located on both vascular 
smooth muscle cells and cardiomyocytes, and have 
been shown to modulate blood vessel vasoconstriction 
and myocardial function.
22,23
 These receptors are also 
expressed in many other organs or cells, such as liver, 
platelets, lymphocytes and monocytes, the central 
nervous system, reproductive organs, retinal 
epithelium, renal mesangial cells, as well as in many 
cell lines, including L6 rat myoblasts. Hiroyama et al. 
generated a knock-out mouse for V1aR (V1aR
-/-
) that 
exhibits an impairment in spatial memory, low blood 
pressure, hypermetabolism of fat and insulin 
resistance.
13
 Interestingly, V1aR
-/-
 mice also displayed 
hyperammonaemia, which was due to increased protein 
catabolism, thereby suggesting that AVP plays a role in 
regulating the balance between protein synthesis and 
degradation.
13
 
The V1b subtype was recently identified in the anterior 
pituitary, where it stimulates the release of ACTH. The 
V2 receptor is mainly expressed in the kidney and is 
responsible for the antidiuretic function of the 
hormone.
20
 AVP binding promotes the phosphorylation 
and desensitization of V1a and V2 receptors. The 
V1aR is internalized in the cytosol, dephosphorylated 
and rapidly returns to the cellular surface. Conversely, 
V2 receptors associate with β-arrestin and remain in 
the cytosol for a longer period of time.
20,24
 The OT 
receptor (OTR), similarly to V2 receptors, is 
internalized and is mainly associated with the clathrin-
dependent pathway. The expression of OTR has been 
detected and characterized in brain, myometrium, 
mammary gland, endometrium, decidua, ovary, as well 
as in the male reproductive apparatus, thymus, heart 
and kidney,
25
 on the surface of vascular endothelial 
cells, osteoblasts, cardiomyocytes and human satellite 
cells.
18
 Owing to their homology in sequence and 
structure, both AVP and OT receptors bind AVP and 
OT with different affinities: AVP binds to OTR in a 
non-selective manner, whereas OT interacts with V1aR 
with a low efficiency.
20
 
Biological effects of AVP and OT on myogenic 
cells in culture 
The first evidence of the biological effects of 
neurohypophyseal hormones as modulators of skeletal 
muscle differentiation came from cell culture 
experiments. In 1995, Nervi et al. showed that the 
addition of AVP to the culture medium of L6 or L5 
myoblasts or mouse satellite cells resulted in a marked 
increase in the percentage of fusion and in the 
formation of hypertrophic myotubes, in the absence of 
significant effects on cell proliferation. The expression 
of early (Myf-5 and myogenin) and late (myosin, 
acetylcholine receptor [AchR] subunits) myogenic 
differentiation markers was increased by the 
neurohypophyseal hormone in a structure- and 
concentration-dependent fashion.
26
 Using a serum-free 
culture medium for L6 and L5 myoblasts and for 
mouse satellite cells, we demonstrated that AVP is 
sufficient to induce robust myogenic differentiation.
27
 
These data confirmed the role of AVP as a positive 
regulator of terminal differentiation in myogenic cells. 
Recent in vitro studies have demonstrated that the 
expression of the V1aR receptor is modulated during 
myogenic differentiation,
28
 which points to the 
physiologic involvement of AVP in myogenesis. This 
hypothesis is supported by data highlighting the 
presence of high levels of immunoreactive AVP in 
both human and mouse embryonic and fetal muscles,
17
 
as well as by the presence of a vasopressin-like peptide 
in the mammalian sympathetic nervous system.
29
 
Interestingly, as reported by Nervi, it is not only AVP, 
but also OT that is involved in myogenic 
differentiation.
26
 Indeed, evidence has been provided of 
the presence of functional OTRs in human myoblast 
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obtained from clonal cultures of postnatal satellite 
cells.
18
 
Biological effects of neurohypophyseal hormones 
on cardiomyocytes 
A new role for AVP in cardiomyogenesis has emerged 
in recent years. Several studies have shown that AVP 
increases the rate of protein synthesis in 
cardiomyocytes of mice and rats, thereby exerting a 
hypertrophic effect mediated by V1aR.
13,30
 The effect 
of AVP on differentiation has been reported on atrial 
and ventricular precursor cells through the AVP 
receptors V2R and V1aR, respectively.
31
 Taken 
together, these findings highlight the possible role of 
this nonapeptide in cardiomyogenesis and heart 
homeostasis. 
Evidence of the role of OT even in cardiac 
differentiation has emerged from experiments 
involving stem cell lines. Paquinet al. examined the 
role of OT using P19 embryonic stem cells which, 
instead of giving rise to all germ layer cell derivatives, 
differentiated into beating cardiomyocytes after 
treatment with 0.1 µM OT.
32
 Furthermore, it was 
demonstrated that the cardiogenic action of OT is 
specifically mediated by OTR. In addition, Hatami et 
al. confirmed that OT treatment of embryonic stem 
cells induces them to differentiate into functional 
cardiomyocytes that are responsive to cardioactive 
 
 
Fig 1. Schematic representation of AVP-dependent signaling pathways in myogenic cells. The transduction of AVP 
signal in myogenic cells involves the activation of PLC and PLD. PLC hydrolyzes phosphatidylinositol 4,5-
bisphosphate, producing the second messengers DAG and IP3. DAG also derives from PA produced by 
PtdCho via PLD. DAG activates the protein kinase C (PKC), while IP3 is responsible for Ca
2+
 release from 
the endoplasmic reticulum into the cytosol. An increased intracellular cytosolic Ca
2+
 concentration activates 
the CaMK pathway, thus inducing cytosolic compartmentalization of class II HDACs. Calcium signaling also 
activates CnA, which in turn promotes the dephosphorylation and the consequent nuclear import of the NFAT 
family. In the nucleus, NFAT gives rise to the formation of multifactorial complexes with MEF2 and GATA2 
in the promoter region of muscle specific genes. The absence of class II HDACs is also likely to promote this 
transcriptional activation, leading to the activation of the skeletal muscle differentiation program. AVP also 
interferes with the cAMP signaling system: PA (produced by PLD-dependent hydrolysis of PtdCho) activates 
PDE4, which in turn promotes cAMP breakdown, thus inhibiting cAMP-dependent activation of PKA, a 
kinase known to negatively regulate myogenic differentiation. 
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drugs, with the typical ultrastructure and expression of 
multiple cardiac-associated molecular markers.
33
 
Collectively, the results of these studies, most of which 
were performed in culture, strongly suggest that both 
AVP and OT are involved in the processes of 
myogenic and cardiomyogenic differentiation. 
Neurohypophyseal hormones activate a complex 
network of intracellular signals in myogenic cells 
The discovery of the expression of OT and AVP 
receptors in many myogenic cells, together with the 
knowledge of the decrease in AVP concentrations 
during gestation
17
 and their increase upon physical 
exercise (see section: Physiological role of 
neurohypophyseal hormones on muscle development 
and homeostasis), point to a physiological role of OT 
and AVP in skeletal muscle development or 
homeostasis. This has, in turn, led to studies being 
conducted to shed light on signaling  in this tissue. 
Most of these studies have focused on AVP-dependent 
signaling, which is now well characterized. 
Conversely, little is known about OT signaling in 
skeletal muscle, the only exception being that OT 
regulates glucose uptake via AMPK in a calcium-
dependant manner.
34
 
Role of phospholipases C and D in vasopressin-
dependent myogenic differentiation 
Transduction of the AVP signal in myogenic cells 
(Figure 1) involves the activation of phospholipases C 
and D (PLC, PLD). AVP induces concentration-
dependent (in the 0.1 nM - 1 µM range) stimulation of 
PLC activity and regulates the intracellular pH with 
mechanisms involving both Na
+
 and anion transports 
across the plasma membrane. Inositol 1,4,5-
trisphosphate (IP3) production is maximally stimulated 
within 2–5 sec of AVP treatment, immediately 
followed by Ca
2+
 release from intracellular stores. 
Activation of protein kinase C by phorbol esters, as 
well as the administration of antagonists of AVP for 
the binding of V1Rs, inhibits these responses.
19
 
AVP stimulation of myogenic cells also results in the 
activation of PLD-dependent phosphatidylcholine 
(PtdCho) breakdown. AVP induces the monophasic 
generation of phosphatidic acid (PA) and the biphasic 
increase in sn-1,2-diacylglycerol (DAG), consisting in 
a rapid peak (within 5 sec of AVP treatment, resulting 
from PLC activity), followed by a sustained phase. 
PLD activation is elicited at AVP concentrations that 
are two orders of magnitude lower than those required 
for PLC activation (EC50 = 0.4 nM vs EC50 = 50 nM, 
respectively),
35
 thereby suggesting that this pathway 
may play a role at physiological concentrations of the 
hormone. 
AVP-dependent activation of PLD causes hydrolysis of 
conspicuous amounts of plasma membrane PtdCho in 
L6 myoblasts. PtdCho de novo synthesis is rapidly 
activated, along with microtubule dependent vesicle 
traffic. By fusing newly formed, PtdCho enriched 
vesicles with the plasma membrane, the physiological 
level of PtdCho is rapidly (within 5 min) restored.
36,37
 
cAMP hydrolysis is required for vasopressin-
dependent stimulation of myogenesis 
AVP treatment of myogenic cells not only induces an 
obvious cross-talk between PLD and PLC signaling 
pathways, but also interferes with the cAMP signaling 
system. It is well known that [cAMP-dependent protein 
kinase (PKA)] negatively regulates myogenic 
differentiation by inhibiting the activity of myogenic 
helix-loop-helix transcription factors 
38,39
 In AVP 
treated L6 cells, selective stimulation of specific 
cAMP-phosphodiesterase isoforms, such as 
phosphodiesterase E4 (PDE4), has been observed in 
response to PA production by PLD.
40
 Accordingly, 
cAMP levels and PKA activity are down-regulated by 
AVP, ultimately allowing the nuclear translocation and 
transcriptional activity of myogenesis regulatory 
factors, myogenin and MyoD.
41,42
 Interestingly, in the 
L6 myogenic cell line, which is maintained quiescent 
by serum deprivation, the addition of AVP restores the 
ability of IGFI to induce differentiation through 
modulation of PDE4 activity.
43
 Furthermore, unlike 
IGFs, AVP stimulates myoblast fusion and does not 
increase proliferation.
26
 AVP is reported to exert its 
pro-myogenic effects not only on L6 myoblasts but 
also on primary satellite cells, by up-regulating the 
expression of muscle-specific genes, such as Myf-5, 
myogenin, myosin heavy chain (MHC), muscle 
creatine kinase (MCK) and AChRs.
43,44
 
Vasopressin-dependent myogenic cell differentiation 
is mediated by both Ca
2+
/calmodulin-dependent 
kinase and calcineurin pathways. 
Many transcription factors play crucial roles during 
myogenesis. In addition to Myf-5, the MEF2 family 
transcription factors recognizes specific DNA elements 
on the promoter of muscle genes. Skeletal muscle cells 
treated with 0.1 µM AVP displayed an induction of 
MEF2A and MEF2C, which occurred concomitantly 
with myogenin expression, during myoblast to 
myotube transition.
44
 The molecular mechanism of this 
effect involves the dissociation of the class II histone 
deacetylases (HDACs) from MEF2. Indeed, 
translocation of class II HDACs from the nucleus to 
the cytosol allows the transcriptional activation of 
MEF2.
45
 The AVP-dependent increase in intracellular 
cytosolic Ca
2+
 concentrations activates the 
calcium/calmodulin-dependent protein kinase (CaMK) 
pathway. This is sufficient to induce cytosolic 
compartmentalization of class II HDACs, as 
demonstrated by the reduced nuclear export of class II 
HDACs and consequent MEF2 activation induced by 
CaMK inhibitors.
44
 Moreover, during AVP-stimulated 
myogenesis, we noted an increase in the acetylation 
levels of histone H3 associated with the myogenin 
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promoter and the MCK enhancer. However, the AVP-
dependent full activation of the myogenic program 
cannot be sustained by CaMK alone.
46
 An additional 
calcium-dependent pathway involves calcineurin 
(CnA), a serine/threonine phosphatase responsible for 
the dephosphorylation and the consequent nuclear 
import of Nuclear Factor of Activated T-cells (NFAT) 
family.
47
 Myoblasts treated with cyclosporine A (CsA), 
a partial inhibitor of CnA, or transiently transfected 
with the dominant negative construct CnA-KO 
displayed a dramatic down-regulation of myogenic 
differentiation at both the morphological and the 
molecular levels. Moreover, CsA treatment of L6 cells 
inhibited the expression of MEF2, NFATc1 and 
GATA2 (a muscle isoform of the zinc-finger GATA 
family); conversely, AVP administration promoted 
accumulation of these three transcription factors in 
nuclei.
46
 Therefore, on the one hand, AVP stimulates 
the formation of multifactorial complexes, which 
involve MEF2, NFATc1 and GATA2, in the promoter 
or enhancer regions of muscle specific genes via the 
calcineurin pathway; on the other hand, the AVP-
dependent activation of CaMK promotes histone 
acetylation in the same DNA regions, leading to full 
expression of the myogenic differentiation program. 
Physiological role of neurohypophyseal hormones 
on muscle development and homeostasis 
Muscle function is highly dependent on and 
coordinated with blood flow and pressure. Indeed, 
muscle activity induces an exercise pressor reflex, a 
regulatory loop that AVP helps to regulate at the 
neuro-endocrine level.
48,49
 It is worth noting that 
skeletal muscle contraction (e.g. induced by exercise) 
or lack of contraction (e.g., following denervation) can 
influence AVP plasma levels. One of the latest 
examples of this effect is found in the study by 
Liviakis et al., which demonstrates that short-term 
static muscle contraction increases plasma AVP.
50
 In 
that study, higher levels of contraction (>70% of 
maximal tension production) increased plasma AVP by 
approximately 100%, whereas low intensity 
contraction failed to alter systemic concentrations of 
this peptide. The reflex nature of this response was 
confirmed by the fact that high-intensity contraction-
induced increases in plasma levels of AVP were not 
associated with changes in other important variables 
that stimulate the release of this peptide (e.g. increases 
in osmolality and body temperature and decreases in 
plasma volume), and that these increases were 
eliminated by sensory denervation of the contracting 
muscle.
50
 Interestingly, several other reports indicate 
that resistance muscular exercise, which represents a 
hypertrophic signal, results in a significant increase in 
circulating AVP, in both in human and other mammals, 
thus posing the theoretical basis for the physiological 
regulation of muscle hypertrophy by neurohypophyseal 
hormones.
46,51–54
 Furthermore, the calcineurin pathway, 
which is strongly stimulated by AVP, has been shown 
to be essential for muscle regeneration in normal and 
dystrophic animals.
55
 Lastly, determination of muscle 
specificity, which is required in muscle development, 
is finely regulated by the smooth muscle-specific 22-
kDa protein, which is in turn regulated by AVP.
56,57
 A 
large body of evidence shows that the AVP system is 
impaired in several neuromuscular diseases, such as 
amyotrophic lateral sclerosis and multiple sclerosis.
58,59
 
These data strengthen the hypothesis that AVP plays a 
physiological role in skeletal muscle homeostasis. 
Recent findings from our laboratory demonstrate that 
muscle-specific stimulation of AVP signaling induces 
acceleration of satellite cell activation and earlier 
stimulation of the specific pathway involved in muscle 
regeneration. V1aR over-expression in murine injured 
skeletal muscle is responsible for an anticipation and 
amplification of the regeneration program.
60,61
 The 
rapid recovery of injured skeletal muscle is associated 
with the rapid resolution of inflammation, the earlier 
activation and fusion of satellite cells, and the faster 
formation of regenerating fibers. Indeed, in V1aR over-
expressing muscle, the expression levels of 
regeneration/differentiation markers such as Pax7, 
embryonic MHC and myogenin, as well as the 
expression and activity of calcineurin and its 
downstream targets IL-4, are strongly up-regulated and 
hastened when compared with mock transfected 
muscle.
60
 In addition, we showed that intramuscular 
AVP injection promotes skeletal muscle regeneration 
following focal injury and rescues muscle repair and 
force, even when muscle recovery is hampered by 
concomitant Tumor Necrosis Factor (TNF)] 
treatment.
62
 In particular, we demonstrated cross-talk at 
the Heat shock protein 70 (Hsp70) level in muscle: 
while AVP (and pro-myogenic cues) upregulate Hsp70 
levels, TNF (and pro-inflammatory cues) downregulate 
them. Hsp70 interacts with the stem cell marker 
PW1/Peg3, which is, in turn, responsible for TNF-
mediated, caspase-dependent inhibition of stem cell 
differentiation in regenerating muscle,
63
 thus 
suggesting that AVP rescues stem cell participation in 
muscle regeneration via Hsp70-mediated anti-caspase 
activity.
62
 On the basis of these results, we may 
conclude that AVP-V1aR signaling plays an important 
role in skeletal muscle development and homeostasis. 
Several recent studies have pointed to a physiological 
role of neurohypophyseal hormones in muscle 
homeostasis by providing evidence of the role of OT in 
muscle growth. As shown by De Jager et al., treatment 
of cattle skeletal muscle with anabolic steroids 
unexpectedly led to a high expression of the OT-
encoding mRNA, accompanied by a high level of 
circulating OT.
64
 The authors hypothesized that OT 
might be involved in mediating the anabolic effects of 
steroids, considering it to be responsible for the 
increased muscle mass. Although sex steroid status is 
known to be related to OT,
25
 and skeletal muscle is 
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known to express functional OTRs,
18
 the endogenous 
production of the hormone by skeletal muscle was 
unexpected.
64
 Up-regulation of OT mRNA expression 
was also detected in wethers treated with steroid 
hormones.
65
 
Physiological role of neurohypophyseal hormones 
on cardiac muscle development and homeostasis 
Many reports have also highlighted the effects of AVP 
on cardiac muscle homeostasis. High levels of 
immunoreactive AVP are present in newborn rat heart 
and decline in adult rat heart, which suggests that the 
AVP system plays a role in early rat maturation.
66
 
Hiroyama et al. reported that the AVP-V1aR signaling 
pathways play a significant role in cardiac hypertrophy 
in response to pressure overload, a finding that is 
consistent with the results of studies on the 
hypertrophic effect of AVP on cultured neonatal heart 
cells from mice and rats.
13,30
 Hupf et al. also detected 
AVP synthesis in pressure-overloaded, isolated and 
perfused rat hearts.
67
 Other studies have reported that 
the heart raises AVP plasma levels in cardiac 
failure,
12,68,69
 hypothesizing the use of AVP antagonist 
in the treatment of this pathology.
70–72
 In recent 
decades, it has been established that OT plays a 
significant role in cardiac muscle homeostasis. OTRs 
are present in rat atria and ventricle and mediate the 
release of andropin, exerting a negative chronotropic 
effect.
73
 The heart is also capable of synthesizing and 
releasing structurally identical OT from the same gene 
as the neurohypophyseal OT. The presence of OT and 
OTRs in all the chambers suggests that this peptide 
plays an autocrine and/or paracrine role in heart 
development and homeostasis.
74
 
Conclusions 
A large body of evidence that has emerged in the last 
three decades indicates that neurohypophyseal 
hormones, i.e. AVP and OT, are involved in muscle 
development and homeostasis. The effects of AVP on 
myogenic cells, primary stem cells and whole skeletal 
muscle have been widely investigated. Less is known 
about the signaling and function of OT in this tissue. 
Taken together, these observations suggest that it may 
be possible to exploit AVP to treat skeletal muscle 
disease conditions (such as dystrophies, cachexia and 
atrophy). OT instead appears to have a greater effect 
on cardiomyocyte differentiation and heart 
homeostasis, which suggests it may be a good 
candidate in the treatment of various cardiac diseases. 
The findings reported in this review, which 
summarizes novel pathways that regulate muscle 
differentiation and homeostasis, radically change the 
canonical roles of neurohypophyseal hormones and 
pave the way for a more thorough understanding of the 
functions of AVP and OT. 
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